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Abstract
Background: The survival following transarterial chemoembolization (TACE) alone is still low in unresectable
hepatocellular carcinoma (HCC) with almost patients developing disease progression after treatment. There is need
to investigate additional therapeutic options that would intensify the initial response to TACE. The present study
was to retrospectively compare the outcome and evaluate the prognostic factors of stereotactic body radiation
therapy (SBRT) alone or as an adjunct to transarterial embolization (TAE) or TACE in the treatment of HCC >5 cm.
Methods: From January 2011 to April 2015, 77 patients received SBRT followed by TAE or TACE (TAE/TACE + SBRT
group) and 50 patients received SBRT alone (SBRT group). The dose of SBRT was 30–50 Gy which was prescribed in
3–5 fractions. Eligibility criteria were: a longest tumor diameter >5.0 cm and Child-Turcotte-Pugh (CTP) Class A or B.
Exclusion criteria included tumor thrombus, lymph node involvement and extrahepatic metastasis.
Results: The median follow-up period was 20.5 months. Median tumor size was 8.5 cm (range, 5.1–21.0 cm).
Median overall survival (OS) in the TAE/TACE + SBRT group was 42.0 months versus 21.0 months in the SBRT group.
The 1-, 3- and 5-year OS was 75.5, 50.8, and 46.9 % in the TAE/TACE + SBRT group and was 62.4, 32.9, and 32.9 % in
the SBRT group, respectively (P = 0.047). The 1-, 3- and 5-year distant metastasis-free survival (DMFS) was 66.3, 44.3,
and 40.6 % in the TAE/TACE + SBRT group and was 56.8, 26.1, and 17.4 % in the SBRT group, respectively (P = 0.049).
The progression-free survival (PFS) and local relapse-free survival (LRFS) were not significantly different between the
two groups. In the entire patient population, a biologically effective dose (BED10) ≥100 Gy and an equivalent dose
in 2 Gy fractions (EQD2) ≥74 Gy were significant prognostic factors for OS, PFS, LRFS and DMFS.
Conclusions: SBRT combined with TAE/TACE may be an effective complementary treatment approach for
HCC >5 cm in diameter. BED10≥100 Gy and EQD2≥74 Gy should receive more attention when the SBRT plan is
designed.
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Background
According to global cancer statistics, an estimated
782,500 new liver cancer cases and 745,500 deaths oc-
curred worldwide in 2012, with China alone accounting
for approximately 50 % of the total number of cases and
deaths [1]. The main histological subtype of primary
liver cancer occurring worldwide is hepatocellular car-
cinoma (HCC) [1]. Resection or transplantation is the
gold standard for the treatment of early-stage HCC [2].
However, only 10–20 % of newly diagnosed patients have
resectable disease. The majority of HCCs are unresect-
able or non-transplantable at the time of diagnosis.
Transarterial chemoembolization (TACE) is frequently
used as a local treatment option for unresectable or
non-transplantable HCC, which imparts a survival bene-
fit compared to best supportive care [3, 4].
Traditionally, radiotherapy (RT) has played a limited
role in the treatment of HCC due to radiation-induced
liver disease (RILD) and low tolerance of the whole liver
to irradiation with a dose of 30–35 Gy [5]. Recently,
stereotactic body radiation therapy (SBRT) has been in-
vestigated as a research hotspot, in order to provide a
higher biologically effective dose (BED). Encouraging re-
sults have indicated that liver SBRT is safe with a high
rate of local control [6–10].
In the present study, we aimed to retrospectively
compared the long-term survival in combined transarterial
embolization (TAE/TACE) and SBRT, and SBRT alone for
unresectable HCC >5 cm in diameter at our institution.
Methods
Patient population
From January 2011 to April 2015, 127 patients with
unresectable HCC were treated with SBRT alone or as
an adjunct to TAE/TACE. Eligibility criteria included: (a)
primary HCC was diagnosed by surgeon, and/or radiolo-
gist and oncologist, according to the international guide-
lines for the management of HCC or by pathology [2],
(b) longest tumor diameter >5.0 cm, (c) Child-Turcotte-
Pugh (CTP) Class A or B disease, and (d) Eastern
Cooperative Oncology Group (ECOG) score 0–1.
Exclusion criteria were: (a) tumor thrombus, (b) lymph
node involvement and extrahepatic metastasis, (c)
ECOG ≥2, and (d) poor liver function in CTP C disease.
Patients without increased CTP score and hepatic en-
zyme (ALT or/and AST) higher than normal before TAE/
TACE, were treated with SBRT after TAE/TACE following
an interval of 3 to 4 weeks. Patients with a hepatic arterio-
venous fistula or who refused to undergo TAE/TACE
received SBRT only. Patient characteristics in the TAE/
TACE+ SBRT group and the SBRT group are shown in
Tables 1 and 2. All patients provided written informed con-
sent. Ethical approval was obtained from the Medical Ethics
Committee of Rui Kang Hospital, Guangxi, China.
TAE/TACE
TAE procedure: selective arteriography of the hepatic ar-
tery was performed to locate the tumor. After identifying
the tumor-feeding artery, 5–20 mL Lipiodol (Huai Hai
Pharmaceutical Factory, Shanghai, China) was slowly
injected through the catheter, which was followed by gel-
atin sponge particle Gelfoam (Jinling Pharmaceutical Co.,
Ltd., Nanjing, China) embolization. TACE procedure: se-
lective arteriography of the hepatic artery was performed
to locate the tumor. After identifying the tumor-feeding
artery, a mixture of 5–20 mL Lipiodol (Huai Hai Pharma-
ceutical Factory, Shanghai, China) and 30–40 mg/m2 cis-
platinum or fluorouracil glycosides 750–1000 mg was
slowly injected through the catheter, which was followed
by gelatin sponge particle Gelfoam (Jinling Pharmaceutical
Co., Ltd., Nanjing, China) embolization. TAE/TACE was
repeated 1 to 4 times at intervals of 4 to 6 weeks.
SBRT
Three or four gold markers (0.8 mm in diameter) were
implanted into the tumor guided by B-ultrasound or CT.
One week later, CT scan and MRI were performed with a
slice thickness of 3 mm. Image fusion CT and MRI delin-
eated the gross tumor volume (GTV) and was expanded
by 0–3 mm to form the planning target volume (PTV).
CyberKnife Robotic Radiosurgery (Accuray Inc., Sunny-
vale, CA, USA) involved use of the Synchrony respiratory
motion-tracking system and patients wore a special







Age≥60/<60 years 60/17 39/11 0.992




CTP class (A/B) 70/7 41/9 0.139
ECOG (0/1) 60/17 39/11 0.545
Nodules (solitary/multiple) 50/27 37/13 0.283
Recurrent/Primary 10/67 5/45 0.324
BCLC (A/B) 50/27 37/13 0.283
Liver cirrhosis (Yes/No) 57/20 38/12 0.485
AFP≥100 ng/mL (Yes/No) 44/33 30/20 0.562
Tumor size (5–10 cm/≥10 cm) 51/26 43/7 0.013*
EQD2 (≥/<74Gy) 49/28 43/7 0.150




AFP alpha fetoprotein, BED biologically effective dose, BCLC Barcelona clinic
liver cancer, CTP Child–Turcotte–Pugh, EQD2 equivalent dose in 2Gy fraction,
ECOG Eastern cooperative oncology group, Fr fractions, SBRT stereotactic body
radiation therapy, TACE/TAE trans-arterial embolization; *P < 0.05
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Synchrony vest. The average treatment time was 30–
60 min. A dose of 30–50 Gy was prescribed in 3–5 frac-
tions at the 66 % (range, 56–80 %) isodose line.
The dose–volume constraints for organs at risk
(OARs) were: duodenum: V 1 mL <25 Gy; stomach and
small bowel: V 1 mL <25 Gy; kidneys: 1/3 Vtotal <15 Gy;
liver: total spared volume (Vtotal-V15Gy) >700 mL and/or
V15Gy <1/3Vtotal; and spinal cord: V 1 mL <15 Gy.
The CyberKnife platform utilized 95–230 beams. Max-
imum spinal cord point dose was a mean of 6.5 Gy
(range, 4.2–12.9 Gy), which was strictly maintained at
1 mL <15 Gy. Maximum bowel point dose was a mean
of 21.2 Gy (range, 8–29.9 Gy) for the PTV, which was
strictly maintained at 1 mL <25 Gy. Liver total spared
volume: V total-V15Gy was a mean of 810 mL (range,
600–1330 mL) and/or V15Gy <1/3Vtotal. According to the
standard equation, the biologically effective dose (BED)
and equivalent dose in 2 Gy fractions (EQD2) assumed
an α/β ratio of 10 for rapidly proliferating tumor cells
and 3 for normal tissues.
Adjuvant therapy
During SBRT treatment, combined adjuvant medication
was administered, consisting of lansoprazole, glutathi-
one, vitamins and Chinese herbs. Antiviral therapy with
a nucleoside or nucleotide analogue was also adminis-
tered to patients with chronic hepatitis due to hepatitis
virus B (HBV) infection.
Response evaluation and follow-up
This study was censored on August 1, 2016. Patients
were re-evaluated one month after SBRT and every three
months thereafter by the treating radiation oncologist.
Clinical examination, determination of alpha fetoprotein
(AFP) and contrast-enhanced CT and/or MRI were per-
formed at each follow-up visit. The Response Evaluation
Criteria in Solid Tumors (RECIST) guideline was used
to describe changes in the treated areas [11].
Toxicity
Toxicity induced by SBRT was scored according to the
NCI Common Terminology Criteria for Adverse Events
(CTCAE) version 4.03. RILD was defined as an anicteric
elevation in alkaline phosphatase of at least 2-fold the
upper normal level (classic RILD) or elevated transami-
nases of at least 5-fold (non-classic RILD), without
progressive disease (PD) and the development of
Table 2 Univariate analysis and multivariate analysis of prognostic predictors for OS and DMFS in 127 locally unresectable HCC
patients







analysis1-year 3-year 1-year 3-year
Gender Male 112 71.1 46.3 0.275 63.1 38.8 0.568
Female 15 66.7 34.6 60.0 35.0
Age, years ≥60 29 69.9 45.1 0.740 68.7 48.5 0.558
<60 98 70.9 43.2 61.2 35.9
AFP≥100 ng/mL Yes 74 63.4 33.4 0.009* 0.057 55.8 28.2 0.022* 0.081
No 53 80.3 61.1 70.2 52.5
BCLC stage A 87 67.5 45.0 0.924 60.6 37.8 0.934
B 40 76.9 44.6 66.8 39.5
CTP class A 111 74.0 45.3 0.112 66.1 39.4 0.099
B 16 60.6 44.6 36.1 27.0
TACE/TAE Yes 77 75.5 50.8 0.047* 0.017* 66.3 44.3 0.049* 0.011*
No 50 62.4 32.9 56.8 26.1
BED10 (Gy) ≥100 44 87.8 62.0 0.005* 0.049* 80.2 50.2 0.006* 0.023*
<100 83 61.4 35.4 53.3 30.6
Tumor size (cm) 5–10 94 77.2 47.3 0.048* 0.137 67.2 42.0 0.064 0.053
≥10 33 51.8 39.1 49.8 28.9
EQD2 (Gy) ≥74 88 75.4 52.0 0.046* 0.051 68.0 46.3 0.008* 0.035*
<74 39 59.9 28.1 51.2 21.6
CTP Child–Turcotte–Pugh, SBRT stereotactic body radiation therapy, AFP alpha fetoprotein, BED biologically effective dose, EQD2 equivalent dose in 2Gy fraction,
OS overall survival, DMFS distant metastasis-free survival, TACE/TAE trans-arterial embolization; *P < 0.05
BED ¼ d  n 1 þ d= α=βð Þf g; EQD
¼ d  n α=β þ dð Þ= α=β þ dxð Þf g;
d ¼ dose; n ¼ fraction and dx ¼ 2ð Þ:
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nonmalignant ascites [12]. Treatment-associated compli-
cations were scored according to the NCI CTCAE ver-
sion 4.03. To verify late adverse effects on liver function,
deterioration in the CTP score after 6 months was also
determined in evaluable patients, defined as alive with-
out PD or intrahepatic recurrence, and having received
no additional therapy in the 6 months after completion
of SBRT.
Statistical analysis
SPSS version 17.0 (IBM Corp., Armonk, NY, USA) was
used for statistical analysis. A Kaplan–Meier curve was
used to calculate the OS, PFS, LRFS, and DMFS rates.
OS was calculated from the date of SBRT treatment
until the date of final follow-up or death. PFS was esti-
mated from the date of SBRT treatment until the date of
disease progression or death. LRFS was estimated from
the date of SBRT treatment until the date of intrahepatic
recurrence or death. DMFS was estimated from the date
of SBRT treatment until the date of extrahepatic metas-
tases or death. The log-rank test was used to compare
outcomes among survival curves for each potential prog-
nostic factor. Any factors that were significant in univar-
iate analyses were subjected to multivariate analyses
using the Cox proportional hazards regression model.
For comparisons between the baseline variables, the X2




In total, 77 patients received TAE/TACE + SBRT and
50 patients received SBRT alone in Rui Kang
Hospital, Nanning, China. Median patient age was
51 years (range, 21–86 years) and 112 patients were
male. One hundred and eleven patients (86.4 %) had
CTP Class A disease. Eighty-seven patients had Bar-
celona Clinic Liver Cancer (BCLC) A stage disease.
Thirty-three patients had HCC with the largest
diameter ≥10 cm. Patient characteristics are shown
in Tables 1 and 2.
TAE/TACE + SBRT versus SBRT alone
During the follow-up period, 58 patients (45.7 %) died
(Table 3). Median OS in the TAE/TACE + SBRT group
was 42.0 months versus 21.0 months in the SBRT group.
The 1-, 3- and 5-year OS was 75.5, 50.8, and 46.9 % in the
TAE/TACE + SBRT group and was 62.4, 32.9, and 32.9 %
in the SBRT group, respectively (P = 0.047). The 1-, 3- and
5-year DMFS was 66.3, 44.3, and 40.6 % in the TAE/
TACE + SBRT group and was 56.8, 26.1, and 17.4 % in the
SBRT group, respectively (P = 0.049). PFS and LRFS were
not significantly different between the two groups (Fig. 1).
Toxicity
The most common toxicities were grade ≤2 (Table 4). In
SBRT group, RILD was observed in one patient with CTP
B who died 3 months after SBRT treatment. Five patients
experienced grade 3/4 toxicity in the SBRT group. No
acute grade 5 toxicities were observed. Four of these pa-
tients recovered with conservative treatment. After
6 months, worsening of CTP score by one points was ob-
served in one A5, and one B7 patient. Worsening of CTP
score by two points was observed in one B7 patient.
In TAE/TACE + SBRT group, RILD was observed
in one CTP A patient and one CTP B patient. Six
patients experienced grade 3/4 toxicity and one pa-
tient experienced grade 5 liver failure. Six of these
patients recovered with conservative treatment. After
6 months, worsening of CTP score by one points
was observed in two A5, one A6 and one B7 pa-
tients. worsening of CTP score by two points was
observed in one A5 patient.
OS, PFS, LRFS, and DMFS
The median follow-up period was 20.5 months (range,
2–66 months) in the entire patient population. Median
tumor size was 8.5 cm (range, 5.1–21.0 cm). The median
OS was 26.0 months and the 1-, 3- and 5-year OS was
70.5, 44.8, and 42.0 %, respectively. The median DMFS
was 23.0 months and the 1-, 3- and 5-year DMFS was
65.4, 38.2, and 32.1 %, respectively. The median PFS was
11.0 months and the 1- and 3-year PFS was 39.2 and
25.8 %, respectively. The median LRFS was 12.0 months
and the 1- and 3-year LRFS was 48.1 and 26.8 %,
respectively.
Prognostic factors for OS and DMFS
Prognostic factors evaluated by univariate and multivariate
analyses included gender, age, AFP, BCLC stage, CTP
class, BED10, EQD2, tumor size and TAE/TACE (Table 4).
Table 3 Causes of death analysis in the two groups
Characteristics TAE/TACE + SBRT group SBRT group
Cases of death 33 25
Causes of death
Tumor-related 30 21
Non tumor-related 3 4
Local tumor-related 15 6
Metastasis-related 15 15
Cases of death within 6 months 8 9
Causes of death within 6 months
Radiation-induced liver disease 2 1
Tumor progression 6 8
SBRT stereotactic body radiation therapy, TACE/TAE transarterial embolization
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Univariate analysis with log-rank test identified five
significant prognostic factors for OS: TAE/TACE, tumor
size, EQD2 (Fig. 2a), BED10 (Fig. 3a) and AFP ≥100 ng/
mL. Multivariate analysis using the Cox model identified
two significant prognostic factors for OS: TAE/TACE
and BED10 (all P < 0.05).
Univariate analysis with the log-rank test identified four
significant prognostic factors for DMFS: TAE/TACE, EQD2
(Fig. 2b), BED10 (Fig. 3b) and AFP ≥100 ng/mL. In addition,
TAE/TACE, BED10, and EQD2 were significant prognostic
factors for DMFS when each continuous variable was en-
tered individually into the Cox model (P < 0.05).
Discussion
HCC is a highly prevalent disease in many Asian coun-
tries, accounting for 80 % of cases worldwide. Less than
20 % of HCC patients are surgical candidates at diagno-
sis [13]. TACE is frequently used as a local treatment
option for unresectable or non-transplantable HCC,
which imparts a survival benefit compared to best sup-
portive care [3, 4]. The BCLC staging system recom-
mends TACE as the standard treatment for intermediate
stage disease. Tumor response rate to TACE ranged
from 17 to 61.9 %, but complete tumor response is very
low (0–4.8 %) as relapse occurs due to intracapsular or
Table 4 Toxicity in the two groups after SBRT in 6 months
Toxicity (Grade) TAE/TACE + SBRT group SBRT group P
value1 2 ≥3 1 2 ≥3
Epigastric discomfort 5 1 1 4 0 1
Nausea 3 1 0 2 1 0
Vomiting 2 1 2 1 0 1
Anemia 2 0 0 2 1 0
Gastric ulcer 0 0 1 0 0 1
Fatigue 4 2 0 3 1 0
Liver failure 0 0 2 0 0 1
Gastrointestinal hemorrhage 0 0 1 0 0 1
Total 16/77 5/77 7/77 12/50 3/50 5/50 0.442
ALT alanine aminotransferase, AST aspartate aminotransferase, SBRT stereotactic body radiation therapy, TACE/TAE transarterial embolization
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Fig. 1 TAE/TACE + SBRT group versus SBRT group. a OS; b DMFS; c LRFS; d PFS
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Fig. 3 BED10 ≥100 Gy was a significant prognostic factor. a OS; b DMFS; c LRFS; d PFS





















































































































Fig. 2 EQD2≥74 Gy was a significant prognostic factor. a OS; b DMFS; c LRFS; d PFS
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extracapsular invasion by HCC. The long-term survival
rates are very low for TACE (5-year OS:1–8 %) [14].
Local treatments for unresectable HCC commonly
used in combination with TAE/TACE for unresect-
able HCC are thermal ablation, percutaneous ethanol
injection, and radiation therapy in Asian countries
[13, 15]. Numerous clinical studies have reported
improved outcomes using TACE + RT combination
therapy compared with TACE [16–18] or RT alone
[19]. SBRT has been investigated as a research hot-
spot in order to provide a higher BED. Encouraging
results have indicated that SBRT is a safe therapy
with a high rate of local control in patients with
HCC [10, 20–22].
Combined TACE and SBRT may be a new treatment
approach for unresectable HCC. Honda et al. retrospect-
ively evaluated 28 patients with small HCCs treated with
TACE followed by SBRT. The median disease-free sur-
vival time was 18 months. The local control (LC) and
OS at 1 year was 96.3 and 92.6 %, respectively. None of
the patients experienced severe acute hematological or
physical toxicity or radiation-induced liver damage [23].
Kang et al. reported the findings of a phase 2 trial of
HCC patients (median longest diameter 29 mm, range
13–78 mm) treated with SBRT after incomplete TACE.
All patients underwent TACE 1–5 times before SBRT.
SBRT doses ranged from 42 to 60 Gy in 3 fractions and
complete response was 38.3 % at 6 months. The LC, OS
Fig. 4 SBRT can result in a complete response in huge HCCs. a TAE + SBRT; b TAE + SBRT; c TAE + SBRT; d SBRT only
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and PFS at 2 years were 94.6, 68.7 and 33.8 %, respect-
ively. In addition, 6.4 % of patients experienced grade 3
gastrointestinal toxicity and 4.3 % of patients experi-
enced grade 4 gastric ulcer perforation [24]. Jacob et al.
reported that local recurrence was significantly de-
creased in the TACE + SBRT group compared with the
TACE only group (10.8 % versus 25.8 %, P = 0.04). After
censoring for liver transplantation, OS was significantly
increased in the TACE + SBRT group compared with the
TACE only group (33 months versus 20 months, P =
0.02) [25]. In the present study, we report long-term sur-
vival following combined TAE/TACE and SBRT versus
SBRT alone for unresectable HCC >5 cm. Our previous
study demonstrated that SBRT is an alternative treat-
ment for small (≤5 cm) HCC, with OS at 1, 3, and 5 years
of 94.1, 73.5, and 64.3 %, respectively [26]. In the current
study, median OS in the TAE/TACE + SBRT group was
better than that in the SBRT only group. The 1-, 3- and 5-
year OS was 75.5, 50.8, and 46.9 % in the TAE/TACE +
SBRT group and was 62.4, 32.9, and 32.9 % in the SBRT
group, respectively (P = 0.047). Therefore, SBRT combined
with TAE/TACE may be an effective complementary treat-
ment approach for HCC >5 cm.
Radiation dose and fractions varied during SBRT.
EQD2 ≥74 Gy (Fig. 2) and BED10 ≥100 Gy (Fig. 3) were
significant prognostic factors for DMFS, LRFS, PFS and
OS. If tolerated by normal tissue, BED10 ≥100 Gy was
also recognized as radiation “ablation” at other sites [27].
The 5-year OS was 55.8 % in BED10 ≥100 groups based
on the findings in our study. However, the lesions with
cumulative GTV >5 cm could be caused by the applica-
tion of a non-ablative dose (BED10 <100 Gy). Based on
the findings in our study, EQD2 ≥74 Gy may be recom-
mended as the “underscore” for a second-line scheme,
the 5-year OS was 48 %. And EQD2 <74 Gy may be rec-
ommended as palliative irradiation, the 4-year OS was
28.1 %. If tolerated by normal tissues, BED10 ≥100 Gy
and EQD2 ≥74 Gy should receive more attention when
the SBRT plan is designed.
Que et al. reported the findings of 22 patients with
huge unresectable HCCs (≥10 cm) treated with SBRT at
a dose range of 26–40 Gy in 5 fractions. The 1-year OS
was 50 % with a median survival of 11 months [28]. In
the current study, univariate analysis showed that
tumor size was a significant prognostic factor for OS.
Thirty-three patients with huge HCCs were treated
with SBRT. The 1-, and 3-year OS was 51.8 and 38.3 %,
respectively, and SBRT achieved substantial tumor re-
gression (Fig. 4).
A total of 68 patients received TAE in our hospital
and 9 patients received TACE at another hospital. The
toxicity and side effects in the TAE/TACE + SBRT group
and SBRT group were limited (Table 4). RILD was ob-
served in one CTP A patient and two CTP B patients.
This study has several limitations. First, this was a
retrospective, non-randomized single-center study.
Second, in the in-depth comparative analysis of TAE/
TACE + SBRT and SBRT alone, only a few patients had
CTP class B in the TAE/TACE + SBRT group compared
with the SBRT group (9 % versus 18.0 %, P = 0.139),
BED10 ≥100 Gy was lower in the TAE/TACE + SBRT
group than in the SBRT group (31.2 % versus
42.0 %, P = 0.031) and the percentage of patients
with tumor size ≥10 cm was higher in the TAE/
TACE + SBRT group than in the SBRT group (31.0 %
versus 16.3 %, P = 0.013). The statistical strength
may have decreased and selection bias may have in-
creased. Third, the follow-up period in the entire pa-
tient population was short, which could have
obscured late effects. However, TAE/TACE + SBRT
may be recommended as a treatment for unresect-
able HCC >5 cm. Further multi-institutional pro-
spective studies are warranted to investigate the true
effect of this novel treatment.
Conclusion
SBRT combined with TAE/TACE may be an effective
complementary treatment approach for HCC >5 cm.
BED10 ≥100 Gy and EQD2 ≥74 Gy should receive more
attention when the SBRT plan is designed.
Abbreviations
AFP: Alpha fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate
aminotransferase; BCLC: Barcelona clinic liver cancer; BED: Biologically
effective dose; CT: Computed tomography; CTP: Child-Turcotte-Pugh;
DMFS: Distant metastasis-free survival; ECOG: Eastern cooperative oncology
group; EQD2: Equivalent dose in 2 Gy fraction; GTV: Gross tumor volume;
HCC: Hepatocellular carcinoma; LC: Local control rate; LRFS: Local relapse-free
survival; MRI: Magnetic resonance imaging; NCI CTCAE: Common
terminology criteria for adverse events; OS: Overall survival; P: P-value;
PFS: Progression-free survival; PTV: Planning target volume; RECIST: Response
evaluation criteria in solid tumors; RILD: Radiation-induced liver disease;
RT: Radiotherapy; SBRT: Stereotactic body radiation therapy; TAE/TACE: Trans-
arterial embolization
Acknowledgements
We wish to thank all patients who were involved in this study and our
colleagues at Rui Kang Hospital.
Funding
This study was funded by the Scientific Research Foundation of Guangxi
Traditional Chinese Medical University, China (Grant number: RKZ201009
and P2010069).
Availability of data and materials
The data sets supporting the conclusion of this article is included within
article. The statistical code and dataset are available from the corresponding
author at sutingshi@163.com.
Authors’ contributions
STS and LP contributed equally to this work. STS and LP participated in the
research design, searched the patient database, and conducted the analysis.
STS, LHZ, CT, ZY, HY, GYC, TMY, JHY, LZP, HEC and LP collected the clinical
materials. STS wrote the manuscript. All authors gave the final approval of
the manuscript’s submission for publication.
Su et al. BMC Cancer  (2016) 16:834 Page 8 of 9
Competing interests
The authors declare that they have no competing interest.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical approval was obtained from the Medical Ethics Committee of Rui
Kang Hospital, Guangxi, China. All patients gave written informed consent.
Author details
1Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional
Chinese Medical University, Nanning 530001, Guangxi Zhuang Autonomous
Region, China. 2Cyberknife Center, Rui Kang Hospital, Guangxi Traditional
Chinese Medical University, Nanning 530001, Guangxi Zhuang Autonomous
Region, China. 3Department of Medical Oncology, Rui Kang Hospital,
Guangxi Traditional Chinese Medical University, Nanning 530001, Guangxi
Zhuang Autonomous Region, China.
Received: 31 March 2016 Accepted: 26 October 2016
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. European Association For The Study Of The L, European Organisation For R,
Treatment Of C. EASL-EORTC clinical practice guidelines: management of
hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.
3. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala
M, Muchart J, Sola R, et al. Arterial embolisation or chemoembolisation
versus symptomatic treatment in patients with unresectable
hepatocellular carcinoma: a randomised controlled trial. Lancet.
2002;359(9319):1734–9.
4. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J.
Randomized controlled trial of transarterial lipiodol chemoembolization for
unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71.
5. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo
LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol
Phys. 1995;31(5):1237–48.
6. Cardenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson
MA, Schefter TE, Tudor K, Deluca J, et al. Phase I feasibility trial of
stereotactic body radiation therapy for primary hepatocellular carcinoma.
Clin Transl Oncol. 2010;12(3):218–25.
7. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg
SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, et al. Multi-institutional phase I/
II trial of stereotactic body radiation therapy for liver metastases. J Clin
Oncol. 2009;27(10):1572–8.
8. Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ,
Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, et al.
Stereotactic body radiation therapy for primary and metastatic liver tumors:
A single institution phase i-ii study. Acta Oncol. 2006;45(7):831–7.
9. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar
LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver
metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371–8.
10. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE,
Kassam Z, Ringash J, Cummings B, et al. Sequential phase I and II trials of
stereotactic body radiotherapy for locally advanced hepatocellular
carcinoma. J Clin Oncol. 2013;31(13):1631–9.
11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for
hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
12. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, Ten Haken
RK. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;
76(3 Suppl):S94–100.
13. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung
JW, Chow P, et al. Asian consensus workshop report: expert consensus
guideline for the management of intermediate and advanced
hepatocellular carcinoma in Asia. Oncology. 2011;81 Suppl 1:158–64.
14. Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van
Gulik TM. Outcome of regional and local ablative therapies for hepatocellular
carcinoma: a collective review. Eur J Surg Oncol. 2005;31(4):331–47.
15. Chen MS, Peng ZW, Xu L, Zhang YJ, Liang HH, Li JQ. Role of radiofrequency
ablation in the treatment of hepatocellular carcinoma: experience of a
cancer center in China. Oncology. 2011;81 Suppl 1:100–4.
16. Huo YR, Eslick GD. Transcatheter Arterial Chemoembolization Plus Radiotherapy
Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A
Systematic Review and Meta-analysis. JAMA Oncol. 2015;1(6):756–65.
17. Zou LQ, Zhang BL, Chang Q, Zhu FP, Li YY, Wei YQ, Guan YS. 3D conformal
radiotherapy combined with transcatheter arterial chemoembolization for
hepatocellular carcinoma. World J Gastroenterol. 2014;20(45):17227–34.
18. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, Zhang RM. Transcatheter
arterial chemoembolization in combination with radiotherapy for
unresectable hepatocellular carcinoma: a systematic review and meta-
analysis. Radiother Oncol. 2009;92(2):184–94.
19. Cheng JC, Chuang VP, Cheng SH, Huang AT, Lin YM, Cheng TI, Yang PS,
You DL, Jian JJ, Tsai SY, et al. Local radiotherapy with or without
transcatheter arterial chemoembolization for patients with unresectable
hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2000;47(2):435–42.
20. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung
KW. Long-term effect of stereotactic body radiation therapy for primary
hepatocellular carcinoma ineligible for local ablation therapy or surgical
resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010;10:475.
21. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M,
Dawson LA. Phase I study of individualized stereotactic body radiotherapy
for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin
Oncol. 2008;26(4):657–64.
22. Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croise-Laurent
V, Barraud H, Ayav A, Bronowicki JP, Peiffert D. Stereotactic body radiation
therapy as an ablative treatment for inoperable hepatocellular carcinoma.
Radiother Oncol. 2015;115(2):211–6.
23. Honda Y, Kimura T, Aikata H, Nakahara T, Naeshiro N, Tanaka M, Miyaki D,
Nagaoki Y, Kawaoka T, Takaki S, et al. Pilot study of stereotactic body radiation
therapy combined with transcatheter arterial chemoembolization for small
hepatocellular carcinoma. Hepatogastroenterology. 2014;61(129):31–6.
24. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung DH, Kim
KB, Lee DH, et al. Stereotactic body radiation therapy for inoperable
hepatocellular carcinoma as a local salvage treatment after incomplete
transarterial chemoembolization. Cancer. 2012;118(21):5424–31.
25. Jacob R, Turley F, Redden DT, Saddekni S, Aal AK, Keene K, Yang E, Zarzour J,
Bolus D, Smith JK, et al. Adjuvant stereotactic body radiotherapy following
transarterial chemoembolization in patients with non-resectable hepatocellular
carcinoma tumours of >/= 3 cm. HPB (Oxford). 2015;17(2):140–9.
26. Su TS, Liang P, Lu HZ, Liang J, Gao YC, Zhou Y, Huang Y, Tang MY, Liang JN.
Stereotactic body radiation therapy for small primary or recurrent hepatocellular
carcinoma in 132 Chinese patients. J Surg Oncol. 2016;113(2):181–7.
27. Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P,
Fogliata A, Tomatis S, D’Agostino G, et al. The challenge of inoperable
hepatocellular carcinoma (HCC): results of a single-institutional experience
on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;
141(7):1301–9.
28. Que JY, Lin LC, Lin KL, Lin CH, Lin YW, Yang CC. The efficacy of stereotactic
body radiation therapy on huge hepatocellular carcinoma unsuitable for
other local modalities. Radiat Oncol. 2014;9:120.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Su et al. BMC Cancer  (2016) 16:834 Page 9 of 9
